€20 million EIB financing to combat biological threats
The European Investment Bank (EIB) and the French biopharmaceutical company Fabentech have signed a €20 million loan to accelerate the development of broad-spectrum therapeutics to combat biological threats to public health.
The deal is supported by the Health Emergency Preparedness and Response Authority (HERA), set up by the European Commission in the aftermath of the Covid-19 pandemic.
This €100 million initiative aims to support health emergency prevention and preparedness in Europe, particularly in response to deliberate or natural emergence of biological threats.
“Backed by EU4Health, HERA Invest encourages innovation in pandemic and CBRN preparedness”, said Laurent Muschel Director-General of HERA. “Partnerships with biopharmaceutical companies like Fabentech, known for their cutting-edge immunotherapies, align with HERA’s commitment to ensure better preparedness for future crises.”
Fabentech’s FabShield technology platform relies on the production of broad-spectrum polyclonal antibody fragments, designed to neutralise deadly viruses and toxins, including their variants.
This technology aims to anticipate the development and production of medical countermeasures, ensuring a rapid and effective response in public health emergencies.
Ambroise Fayolle, Vice-President of the European Investment Bank, added: “Investment in innovative companies such as Fabentech is essential for strengthening health security in Europe. This funding will enable Fabentech to step up its work in this strategic area for Europe, strengthening our ability to respond to future health crises.”
“We are honoured to receive this support from HERA and the European Investment Bank,” added Sébastien Iva, CEO of Fabentech. “This funding reflects the confidence in our technology and our commitment to safeguarding populations from biological threats. It will allow us to accelerate our initiatives and broaden our impact on a global scale.”
Diana Spencer, Senior Digital Content Editor, DDW
